Glaucoma/Ocular Hypertension Case Study

This case study demonstrates Chiltern’s close collaboration with Sponsor and global scientific efforts to develop clinical study plans with careful assessment of recruitment potential.

PROJECT OVERVIEW:

• A small biotech company engaged Chiltern to co-develop an exploratory proof-of-concept clinical program for prevention of open angle
• glaucoma via a novel neurological approach using intravitreal injections.
• The Phase IIa study could be performed anywhere in the world and required a detailed feasibility assessment.
• Treatment period – 9 months.
• 100 subjects at 20 sites distributed throughout US, Argentina, Brazil, Australia, India, Belgium, Czech Republic, Portugal and Israel.
• This was the first trial of its type, and the Sponsor was working closely with the most renowned international practitioners in the field.